11Jul 2022
A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient‐reported quality of life

A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient‐reported quality of life

The objective of this study was to report acute changes in patient‐reported quality of life (PRQOL) using the 26‐item Expanded Prostate Index Composite (EPIC‐26) questionnaire in a prospective study using hypofractionated intensity‐modulated proton beam therapy (H‐IMPT) targeting the prostate and the pelvic lymph nodes for high‐risk or unfavourable intermediate‐risk prostate cancer. At the end of treatment, there were statistically significant and clinically meaningful declines in UO and BF scores. UO and UI scores showed improvement at 3 months after posttreatment and were similar to the baseline scores. However, the BF score remained lower at 3 months posttreatment with a clinically meaningful decline.

  • #urology

Like

Save

Share